Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Novel Inhibitors against Neuroblastoma

01.07.2013
Neuroblastoma is a malignant cancer, which occurs chiefly in infants. University of Würzburg scientists now present novel inhibitors able to suppress the growth of these tumors in the journal "Cancer Cell".
Neuroblastoma is one of the most common cancers in children up to one year of age. Neuroblastomas develop when certain nerve cells degenerate and form sizable lumps – in most cases in the abdomen of the child. About 130 cases of the disease are diagnosed each year in Germany.

In contrast to many other types of cancer, neuroblastomas sometimes heal spontaneously. In most patients, this type of cancer can be easily treated with conventional drugs. However, the chances of recovery and survival are slim in 20 percent of the cases. The reason: The tumors form metastases that don't much respond to conventional drugs.

Why the tumor becomes aggressive

"The most important factor for a poor prognosis is an amplification of the MYCN gene," says Professor Martin Eilers at the Biocenter of the University of Würzburg. This leads to an increased production of the MYCN protein, which is assumed to be responsible for the aggressive growth and the resistance to therapy of the tumors.

The MYCN protein stimulates cell growth. In normal cells, it can only be active for a short while, because it is quickly degraded. The situation is different in neuroblastomas: There, the protein is protected from fast degradation, because it is bound to a partner protein (Aurora-A). This was shown by Martin Eilers' study group in 2009.

How the novel inhibitors work

Together with an international team, the Würzburg study group has now made further progress in this research: They identified novel inhibitors that are able to disrupt the complex of Aurora-A and MYCN. If aggressive neuroblastomas are treated with these inhibitors, they cease to grow. At least, this is the result of tests in a mouse model.
"This might show the way to the development of new and better drugs against this aggressive tumor," says Eilers. According to the professor, other long-known inhibitors of the Aurora-A protein are already being tested in the first clinical trials in the USA.

The inhibitors of Aurora-A are promising for the treatment of other types of cancer as well: The fatal complex of Aurora-A and the MYCN protein is also present in particularly aggressive prostate carcinomas.

"Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma", Markus Brockmann, Evon Poon, Teeara Berry, Anne Carstensen, Hedwig E. Deubzer, Lukas Rycak, Yann Jamin, Khin Thway, Simon P. Robinson, Frederik Roels, Olaf Witt, Matthias Fischer, Louis Chesler, Martin Eilers, Cancer Cell, 20 June 2013, DOI 10.1016/j.ccr.2013.05.005

Contact person

Prof. Dr. Martin Eilers, Biocenter at the University of Würzburg, T +49 (0)931 888-4442, martin.eilers@biozentrum.uni-wuerzburg.de

Gunnar Bartsch | Uni Würzburg
Further information:
http://www.uni-wuerzburg.de

Further reports about: Biocenter Cancer MYCN Small Molecule aurora-A nerve cell neuroblastoma types of cancer

More articles from Life Sciences:

nachricht Immune Defense Without Collateral Damage
23.01.2017 | Universität Basel

nachricht The interactome of infected neural cells reveals new therapeutic targets for Zika
23.01.2017 | D'Or Institute for Research and Education

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Tracking movement of immune cells identifies key first steps in inflammatory arthritis

23.01.2017 | Health and Medicine

Electrocatalysis can advance green transition

23.01.2017 | Physics and Astronomy

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>